LETTER
Does Race Predispose to Angiotensin-associated Angioneurotic Edema?
Nancy J. Brown and
John H. Nadeau
15 December 1993 | Volume 119 Issue 12 | Page 1224
TO THE EDITOR:
Since the report by Wilkin and colleagues [1] of angioneurotic edema in two patients receiving captopril, many other cases associated with angiotensin-converting-enzyme (ACE) inhibitor therapy have been recognized; the incidence has been estimated to be 0.1% to 0.2% [2]. We have recently observed a higher-than-expected incidence in black patients. We examined the literature on ACE inhibitor-associated angioneurotic edema to determine whether others had noted such a trend. We reviewed 38 articles reporting cases of ACE inhibitor-associated angioneurotic edema since 1980. In 18 articles, patient race was reported for at least one case. Fifty-two of 67 patients whose race was reported were black. Fourteen patients were white, and 1 was Hispanic. Unfortunately, no information about race was provided for most (n = 360) of the cases reported. We therefore cannot conclude whether the apparently high proportion of blacks among patients with ACE inhibitor-associated angioneurotic edema reflects true prevalence or a reporting bias. If real, the high proportion of blacks among patients with ACE inhibitor-associated angioneurotic edema contrasts with the low proportion of blacks among all patients treated with ACE inhibitors [3, 4]. This finding suggests that the incidence of angioneurotic edema in blacks treated with ACE inhibitors may be much higher than the 0.1% to 0.2% cited in the literature. Rigorous pharmacoepidemiologic studies are needed to confirm or refute this observation. In the meantime, we are interested in knowing what racial distribution others have observed among patients with ACE inhibitor-associated angioneurotic edema.
1. Wilkin JK, Hammond JL, Kirkendall WM. The captopril-induced eruption. Arch Dermatol. 1980; 116:902-5.
2. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992; 117:234-42.
3. Cooper WD, Sheldon D, Brown D, Kimber GR, Isitt VL, Currie WJ. Post-marketing surveillance of enalapril:experience in 11,710 hypertensive patients in general practice. J R Coll Gen Pract. 1987; 37: 346-9.
4. Cameron HA, Higgins TJ. Clinical exposure with lisinopril. Observations on safety and tolerability. J Hum Hypertens. 1989; 3:177-86.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
PubMed
Top
References
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
